These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 26220200)

  • 1. Intravenous ω-3 Fatty Acids Plus Gemcitabine.
    Arshad A; Isherwood J; Mann C; Cooke J; Pollard C; Runau F; Morgan B; Steward W; Metcalfe M; Dennison A
    JPEN J Parenter Enteral Nutr; 2017 Mar; 41(3):398-403. PubMed ID: 26220200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Restoration of mannose-binding lectin complement activity is associated with improved outcome in patients with advanced pancreatic cancer treated with gemcitabine and intravenous ω-3 fish oil.
    Arshad A; Chung W; Isherwood J; Steward W; Metcalfe M; Dennison A
    JPEN J Parenter Enteral Nutr; 2014 Feb; 38(2):214-9. PubMed ID: 23423329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
    Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
    Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study.
    Philip PA; Lacy J; Portales F; Sobrero A; Pazo-Cid R; Manzano Mozo JL; Kim EJ; Dowden S; Zakari A; Borg C; Terrebonne E; Rivera F; Sastre J; Bathini V; López-Trabada D; Asselah J; Saif MW; Shiansong Li J; Ong TJ; Nydam T; Hammel P
    Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):285-294. PubMed ID: 31953079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial.
    Bachet JB; Hammel P; Desramé J; Meurisse A; Chibaudel B; André T; Debourdeau P; Dauba J; Lecomte T; Seitz JF; Tournigand C; Aparicio T; Meyer VG; Taieb J; Volet J; Monier A; Bonnetain F; Louvet C
    Lancet Gastroenterol Hepatol; 2017 May; 2(5):337-346. PubMed ID: 28397697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial.
    Neoptolemos JP; Stocken DD; Bassi C; Ghaneh P; Cunningham D; Goldstein D; Padbury R; Moore MJ; Gallinger S; Mariette C; Wente MN; Izbicki JR; Friess H; Lerch MM; Dervenis C; Oláh A; Butturini G; Doi R; Lind PA; Smith D; Valle JW; Palmer DH; Buckels JA; Thompson J; McKay CJ; Rawcliffe CL; Büchler MW;
    JAMA; 2010 Sep; 304(10):1073-81. PubMed ID: 20823433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality of life study of patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma treated with gemcitabine+nab-paclitaxel versus gemcitabine alone: AX-PANC-SY001, a randomized phase-2 study.
    Yalcin S; Dane F; Oksuzoglu B; Ozdemir NY; Isikdogan A; Ozkan M; Demirag GG; Coskun HS; Karabulut B; Evrensel T; Ustaoglu MA; Ozdemir F; Turna H; Yavuzsen T; Aykan F; Sevinc A; Akbulut H; Yuce D; Hayran M; Kilickap S
    BMC Cancer; 2020 Mar; 20(1):259. PubMed ID: 32228512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction in circulating pro-angiogenic and pro-inflammatory factors is related to improved outcomes in patients with advanced pancreatic cancer treated with gemcitabine and intravenous omega-3 fish oil.
    Arshad A; Chung WY; Steward W; Metcalfe MS; Dennison AR
    HPB (Oxford); 2013 Jun; 15(6):428-32. PubMed ID: 23458624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gemcitabine plus enzastaurin or single-agent gemcitabine in locally advanced or metastatic pancreatic cancer: results of a phase II, randomized, noncomparative study.
    Richards DA; Kuefler PR; Becerra C; Wilfong LS; Gersh RH; Boehm KA; Zhan F; Asmar L; Myrand SP; Hozak RR; Zhao L; Gill JF; Mullaney BP; Obasaju CK; Nicol SJ
    Invest New Drugs; 2011 Feb; 29(1):144-53. PubMed ID: 19714296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.
    Von Hoff DD; Ervin T; Arena FP; Chiorean EG; Infante J; Moore M; Seay T; Tjulandin SA; Ma WW; Saleh MN; Harris M; Reni M; Dowden S; Laheru D; Bahary N; Ramanathan RK; Tabernero J; Hidalgo M; Goldstein D; Van Cutsem E; Wei X; Iglesias J; Renschler MF
    N Engl J Med; 2013 Oct; 369(18):1691-703. PubMed ID: 24131140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer.
    Van Cutsem E; van de Velde H; Karasek P; Oettle H; Vervenne WL; Szawlowski A; Schoffski P; Post S; Verslype C; Neumann H; Safran H; Humblet Y; Perez Ruixo J; Ma Y; Von Hoff D
    J Clin Oncol; 2004 Apr; 22(8):1430-8. PubMed ID: 15084616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial.
    Gourgou-Bourgade S; Bascoul-Mollevi C; Desseigne F; Ychou M; Bouché O; Guimbaud R; Bécouarn Y; Adenis A; Raoul JL; Boige V; Bérille J; Conroy T
    J Clin Oncol; 2013 Jan; 31(1):23-9. PubMed ID: 23213101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial.
    Xiong HQ; Rosenberg A; LoBuglio A; Schmidt W; Wolff RA; Deutsch J; Needle M; Abbruzzese JL
    J Clin Oncol; 2004 Jul; 22(13):2610-6. PubMed ID: 15226328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial.
    Mukherjee S; Hurt CN; Bridgewater J; Falk S; Cummins S; Wasan H; Crosby T; Jephcott C; Roy R; Radhakrishna G; McDonald A; Ray R; Joseph G; Staffurth J; Abrams RA; Griffiths G; Maughan T
    Lancet Oncol; 2013 Apr; 14(4):317-26. PubMed ID: 23474363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study.
    Petrioli R; Roviello G; Fiaschi AI; Laera L; Marrelli D; Roviello F; Francini E
    Cancer Chemother Pharmacol; 2015 Apr; 75(4):683-90. PubMed ID: 25618415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of gemcitabine and continuous infusion fluorouracil in advanced pancreatic cancer.
    Rauch DP; Maurer CA; Aebi S; Pampallona S; Friess H; Ludwig CU; Büchler MW; Borner MM
    Oncology; 2001; 60(1):43-8. PubMed ID: 11150907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality of life and outcome of patients with metastatic pancreatic cancer receiving first-line chemotherapy with nab-paclitaxel and gemcitabine: Real-life results from the prospective QOLIXANE trial of the Platform for Outcome, Quality of Life and Translational Research on Pancreatic Cancer registry.
    Al-Batran SE; Hofheinz RD; Reichart A; Pauligk C; Schönherr C; Schlag R; Siegler G; Dörfel S; Koenigsmann M; Zahn MO; Schubert J; Aldaoud A; Höffkes HG; Schulz H; Hahn L; Uhlig J; Blau W; Stauch M; Weniger J; Wolf M; Jacobasch L; Bildat S; Wehmeyer J; Homann N; Trojan J; Waidmann O; Fietz T; Feustel HP; Groschek M; Wierecky J; Waibel K; Mahlmann S; Schwindel U; Peters U; Schuch G; Pink D; Eschenburg H; Wörns MA; Harich HD; von Weikersthal LF; Däßler KU; Behringer DM; Messmann H; Kretzschmar A; Gallmeier E; Forstbauer H; Kunzmann V; Papke J; Büchner-Steudel P; Vehling-Kaiser U; Springfeld C; Vogel A; Ettrich TJ; Schaaf M; Hausen GZ; Götze TO;
    Int J Cancer; 2021 Mar; 148(6):1478-1488. PubMed ID: 33038277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer.
    Morizane C; Okusaka T; Furuse J; Ishii H; Ueno H; Ikeda M; Nakachi K; Najima M; Ogura T; Suzuki E
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):313-9. PubMed ID: 18398614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer.
    Heinemann V; Quietzsch D; Gieseler F; Gonnermann M; Schönekäs H; Rost A; Neuhaus H; Haag C; Clemens M; Heinrich B; Vehling-Kaiser U; Fuchs M; Fleckenstein D; Gesierich W; Uthgenannt D; Einsele H; Holstege A; Hinke A; Schalhorn A; Wilkowski R
    J Clin Oncol; 2006 Aug; 24(24):3946-52. PubMed ID: 16921047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial.
    Middleton G; Palmer DH; Greenhalf W; Ghaneh P; Jackson R; Cox T; Evans A; Shaw VE; Wadsley J; Valle JW; Propper D; Wasan H; Falk S; Cunningham D; Coxon F; Ross P; Madhusudan S; Wadd N; Corrie P; Hickish T; Costello E; Campbell F; Rawcliffe C; Neoptolemos JP
    Lancet Oncol; 2017 Apr; 18(4):486-499. PubMed ID: 28259610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.